Building a Digital-First Pharma Company: Lessons from Organizations Getting It Right

What Digital-First Actually Means

“Digital-first” is one of the more abused terms in pharma strategy. It’s used to describe everything from cloud migration to AI proof-of-concepts to website redesigns. The version that matters operationally is much narrower: a digital-first organization is one where digital capability is the default mechanism for how work is designed, executed, and improved — not an option that’s added to traditional ways of working.

Operationally, this shows up in several ways. Decisions are made with data that’s been engineered for decision support, not assembled in retrospective analyses. New initiatives default to digital execution patterns — automation, real-time monitoring, integrated data flows — rather than treating digital as a phase 2 enhancement. Talent across functions is digitally fluent, not just the central digital team. The technology platforms are stable, integrated, and treated as production assets rather than evolving experiments. Governance includes digital and data considerations as first-class inputs, not afterthoughts.

None of this is exotic. It’s the operating model that digital-native companies in other industries take for granted. What makes it notable in pharma is how rare it remains. Most pharma organizations have functions or business units that operate this way; few have the entire organization operating this way. The digital-first companies have the consistent pattern across the enterprise — and that consistency is what produces the compounding advantages over time.

Operating Model: The Real Differentiator

The operating model is where the digital-first companies separate from the rest. The technology stack and the talent are visible and easier to copy. The operating model is harder to see and harder to replicate because it’s woven into how the organization makes decisions, designs work, and accumulates capability.

A few operating model patterns recur across digital-first pharma companies. Cross-functional product teams own digital capabilities end-to-end rather than having capabilities pass between functional silos. Data and analytics are organized as platforms with explicit ownership and accountability rather than as projects that deliver one-off reports. Decision rights for digital initiatives are clear and reside close to the operational outcomes they affect. The boundary between “the business” and “digital” is blurred — digital leaders are business leaders and business leaders are digitally fluent.

Capability Architecture and Platforms

The capability architecture in digital-first pharma companies tends toward platform thinking. Rather than building point solutions for individual use cases, the organization invests in platforms — data, AI, integration, identity, observability — that multiple use cases ride on. The platforms are explicit products with owners, roadmaps, and customer relationships internally.

Platform thinking has a few practical implications. The first use case on a new platform pays a higher per-unit cost because it’s also funding the platform creation. The second and subsequent use cases ride on much lower marginal cost. This creates an investment pattern that’s harder to defend in traditional ROI frameworks but produces dramatically better economics over time. Digital-first companies have learned to fund platforms separately from use cases and to evaluate platform investment on portfolio outcomes rather than individual use case ROI.

The platforms also create operational discipline. A use case that has to ride on a platform inherits the platform’s standards — data governance, security, validation, observability. This raises the floor on use case quality without each use case having to invent the standards from scratch. Programs without platforms tend to produce wide variance in use case quality because each one is built independently.

The build-vs-buy question

Digital-first pharma companies tend to be deliberate about build-vs-buy decisions. They buy commodity capabilities — collaboration, productivity, basic infrastructure — without trying to build custom alternatives. They build differentiating capabilities — proprietary data platforms, custom AI applications, specialized integration layers — when there’s strategic reason to own the IP. They avoid the middle: heavily customized commercial software that combines the cost of buying with the maintenance burden of building.

The discipline isn’t always present at less mature organizations, where the path of least resistance often produces a system landscape full of moderately customized commercial systems that drift further from vendor support over time. The technical debt accumulates and becomes a major constraint on future capability. Digital-first companies confront this pattern early and either standardize on vendor configurations or invest in proper builds rather than letting heavy customization metastasize.

The Talent Model

The talent model in digital-first pharma companies has two characteristics that distinguish it from traditional patterns. First, digital talent is distributed rather than concentrated. Data engineers, product managers, and software engineers exist in business functions — clinical operations, commercial, manufacturing — not just in a central digital team. This distribution creates the cross-functional fluency that makes the operating model work.

Second, traditional functional talent is digitally fluent. Clinical operations leaders know enough about data architecture and AI to make informed decisions. Manufacturing leaders understand the platform architecture their plants depend on. Commercial leaders work with their analytics partners as collaborators rather than as service providers. This fluency doesn’t make everyone a technologist; it makes everyone a more effective participant in digital decisions.

Building this talent model takes years and deliberate investment. The hiring practices have to change — adding digital screens to traditional pharma roles. Career paths have to evolve so digital talent in business functions has growth opportunities. Training and development have to invest in digital fluency for traditional talent. The compensation philosophy has to recognize that digital talent often commands different market rates than traditional pharma roles.

The companies that get this right have made digital fluency a leadership expectation, not just a technical specialty. The senior leaders are themselves digitally fluent and model the behavior they want from the rest of the organization. Companies where digital fluency stays a specialist’s job tend to plateau short of digital-first status because the operating model can’t shift without leadership-level capability.

Governance and Decision Rights

Governance in digital-first pharma companies is lighter and faster than traditional digital governance, but no less rigorous. The structure tends toward federated decision-making within platform-level guardrails. Use case decisions happen close to the business; platform decisions happen at the level that owns the platform; enterprise-level decisions are reserved for the matters that genuinely require enterprise alignment.

The guardrails are the critical part. Platform governance establishes data standards, security requirements, validation expectations, and integration patterns. Use cases that operate within the guardrails proceed without case-by-case approvals. Use cases that need to deviate from the guardrails go through a defined exception process. This structure produces speed where speed adds value and rigor where rigor adds value, without forcing every initiative through the same gauntlet.

The contrast with traditional pharma digital governance is stark. Traditional governance tends to be approval-heavy at the use case level, with every initiative passing through committees that may or may not have the context to add value. The result is slow decisions, frustrated business sponsors, and a pattern of going around governance rather than through it. Digital-first governance flips this: governance focuses on the architectural decisions where it adds disproportionate value and gets out of the way of the use case decisions where it doesn’t.

Regulatory Alignment as a First-Class Concern

Pharma’s regulatory dimension shapes what digital-first looks like in this industry specifically. The digital-first companies have learned to design their platforms, governance, and operating model with regulatory alignment built in from the start — not retrofitted later.

This shows up in several ways. Validation considerations are part of platform design rather than a separate workstream. Data integrity controls are built into the data architecture. Inspection readiness is a continuous discipline rather than a periodic exercise. The relationship with regulators is collaborative — these companies engage regulatory bodies on emerging digital topics, contribute to industry standards work, and participate in pilot programs for new regulatory frameworks.

The companies that try to be digital-first while treating regulatory alignment as an afterthought consistently encounter friction that slows them down. Audit findings, validation rework, and inspection issues consume bandwidth that should be going into capability building. The digital-first leaders avoid this trap by treating regulatory alignment as integral to the operating model rather than as a constraint imposed on it.

Sequencing the Journey

The path from a traditional pharma operating model to a digital-first one is multi-year. Companies that have made the transition share some sequencing patterns.

They start with operating model design rather than technology selection. The question “how should we work” precedes the question “what should we buy.” Many transformation programs invert this order and end up with technology investments that the operating model can’t fully exploit.

They invest in platforms early, even before the use cases that will ride on them are well-defined. The platform investment creates the foundation for capability that compounds over time. Companies that wait to invest in platforms until after specific use cases are funded usually end up with point solutions that don’t compose into a platform later.

They distribute digital talent into business functions rather than concentrating it in a central team. The central team remains important for platforms, standards, and capability development, but the day-to-day digital fluency lives in the functions where the work happens.

They redesign governance to be lighter at the use case level and more rigorous at the platform level. The shift in governance philosophy is one of the harder behavioral changes for traditional pharma organizations, but it’s foundational for the operating model to actually work.

They invest in leadership capability — ensuring that senior leaders across the enterprise are themselves digitally fluent and capable of leading in a digital-first model. This investment is sometimes uncomfortable and rarely visible to the outside, but it determines whether the operating model holds when pressure mounts.

They commit to the journey at the executive level and protect the investment through cycles of pressure. Digital-first transitions take 5-7 years for organizations of meaningful scale. Companies that lose executive commitment partway through end up with a hybrid that has the costs of the transition without the benefits of completing it.

Becoming digital-first is hard, and the pharma industry’s regulatory and operational complexity makes it harder. But the companies that have made the transition demonstrate that it’s possible — and the operational and competitive advantages they’ve accumulated suggest that the transition is increasingly necessary rather than optional. For the organizations still working through transformation programs, the lessons from those further ahead offer a clearer path. The path requires harder organizational design choices than most transformation programs make, but it’s a path that has been successfully traveled, and the gains for those who travel it are real.

Common Failure Patterns to Avoid

For every digital-first success story in pharma, there are several transformation programs that have stalled, plateaued, or quietly been reframed as something less ambitious. The failure patterns are predictable and worth naming explicitly so they can be recognized and avoided.

The technology-only transformation. The program invests heavily in cloud migration, modern data platforms, and AI tools without addressing operating model, governance, or talent in parallel. The technology is delivered; the business model around it doesn’t change. Capability accumulates without value capture, and eventually the investment is questioned because the business case hasn’t materialized. The fix would have been to invest in operating model and talent alongside technology, but by the time the gap is recognized, the budget has already been spent.

The center-of-excellence trap. The organization establishes a digital center of excellence, hires data scientists and AI experts, and produces impressive proofs of concept that don’t scale. The center delivers projects but the broader organization doesn’t develop digital fluency. Use cases stay in the center rather than embedding in the business. The center grows in isolation and eventually faces credibility pressure when its outputs aren’t producing enterprise-level value.

The transformation-program perpetual motion. Successive transformation programs are launched, each rebooting the agenda of the prior one without sustained delivery. The organization develops fatigue and skepticism. Talented digital leaders cycle through the role and leave when the next reorganization undermines their work. The transformation rhetoric persists while operational reality stays largely unchanged.

The digital department insurgency. The digital function operates in opposition to the rest of the organization, characterizing traditional functions as obstacles and trying to drive change through unilateral initiative. The result is friction rather than transformation. Functions that should be partners become adversaries. Eventually the digital function is reorganized, often with much of its capability dispersed, and the transformation effort is set back by years.

The premature scale. The organization tries to scale digital capability across the enterprise before any single application has been operationalized to production-grade quality. Multiple half-built capabilities consume resources without delivering value. The pattern produces visible activity that satisfies leadership reporting but doesn’t build durable foundations. Eventually maintenance burden of the half-built capabilities exceeds the resources available to address it.

Each of these patterns has a corrective. Technology-only programs need operating model investment. Center-of-excellence programs need distributed capability building. Perpetual transformation cycles need sustained leadership commitment. Insurgent digital functions need partnership-based engagement. Premature scaling needs focus on getting one capability right before broadening. The corrections are recognized in retrospect but rarely applied in time. Naming the patterns explicitly helps leadership recognize them earlier and apply the correction before the pattern has consumed years of effort.

Implications for the Broader Industry

The emergence of digital-first pharma companies has implications beyond the companies themselves. The industry as a whole is starting to bifurcate between organizations that have made the operating model transition and those that haven’t, with consequences that will compound over the coming years.

The digital-first companies are building data assets, capability platforms, and operational discipline that produce compounding advantages. Their development timelines, manufacturing economics, commercial productivity, and decision quality improve year over year as the foundations they invested in start generating returns. The lagging organizations are running on capability that was state-of-the-art a decade ago, with operational economics that look acceptable in isolation but increasingly disadvantaged in competitive comparison.

Talent dynamics will accelerate the divergence. Top digital and analytics talent is increasingly selective about where they work. Digital-first organizations attract better talent more easily; lagging organizations either pay premium compensation for talent that produces less in their environment or accept weaker talent. The talent divide reinforces the capability divide.

M&A and partnership dynamics will also feel the effect. Digital-first companies will be more attractive partners for innovative biotechs, technology companies, and academic collaborators. They’ll be better able to absorb capability acquisitions because their integration approach matches the culture of the targets. Lagging organizations will face progressively narrower partnership and acquisition opportunities at competitive terms.

For organizations on the lagging side of the divide, the implications aren’t catastrophic but they are real. The transition is still possible — the digital-first companies that made the journey did so from starting points not radically different from where many traditional pharma organizations are today. But the transition takes 5-7 years, and the cost of waiting compounds. Organizations that decide to commit in 2026 will be operating in a digital-first model in the early 2030s. Organizations that defer the decision will be operating in their current model for longer, with the competitive gap continuing to widen until they make the commitment.

The encouraging news is that the path is well-mapped, the lessons are real, and the operational benefits are demonstrated. The discouraging news is that the path requires organizational design choices that traditional pharma leadership often resists, and the timeline is longer than most leadership tenures. Meeting both challenges — making the choices and sustaining them across leadership transitions — is the test that determines whether an organization joins the digital-first cohort or stays in the slowly widening gap behind it.

References